Table 5 The effects of gene-gene interactions on the survival of gastric cancer patients received adjuvant chemotherapy.
Combined genotypes | Patients | Deaths | MST (months) | P | HR (95%CI) a |
|---|---|---|---|---|---|
MTRR 66A > G and MTR 2756A > G | |||||
MTRR 66AA + MTR 2756AA | 105 | 54 | 43 | 0.149 | 1 |
MTRR 66AA + MTR 2756GG + GA | 19 | 7 | 65 b | 0.631 (0.287–1.388) | |
MTRR 66GG + GA + MTR 2756AA | 82 | 28 | 81 b | 0.607 (0.384–0.959) | |
MTRR 66GG + GA + MTR 2756GG + GA | 21 | 10 | 60 b | 0.871 (0.443–1.713) | |
MTRR 66A > G and MTHFR 677C > T | |||||
MTRR 66AA + MTHFR 677CC | 57 | 27 | 50 | 0.133 | 1 |
MTRR 66AA + MTHFR 677TT + TC | 77 | 41 | 43 | 1.146 (0.705–1.864) | |
MTRR 66GG + GA + MTHFR 677CC | 34 | 11 | 85 b | 0.588 (0.291–1.187) | |
MTRR 66GG + GA + MTHFR 677TT + TC | 77 | 29 | 64 b | 0.761 (0.451–1.287) | |
TS3-UTR I > D and TS5-UTR 2R > 3R | |||||
TS3-UTR II + TS5-UTR 2R2R | 5 | 5 | 18 | 0.046 | 1 |
TS3-UTR II+ TS5-UTR 2R3R + 3R3R | 16 | 5 | 72 b | 0.223 (0.064–0.776) | |
TS3-UTR DD + DI + TS5-UTR 2R2R | 9 | 5 | 39 | 0.481 (0.139–1.666) | |
TS3-UTRDD + DI+ TS5-UTR 2R3R + 3R3R | 202 | 85 | 73 b | 0.332 (0.134–0.822) | |
